Home Cart 0 Sign in  
X

[ CAS No. 19369-53-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 19369-53-0
Chemical Structure| 19369-53-0
Chemical Structure| 19369-53-0
Structure of 19369-53-0 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 19369-53-0 ]

Related Doc. of [ 19369-53-0 ]

Alternatived Products of [ 19369-53-0 ]

Product Details of [ 19369-53-0 ]

CAS No. :19369-53-0 MDL No. :MFCD01922101
Formula : C7H9NO2S Boiling Point : -
Linear Structure Formula :- InChI Key :GHPDMFBHITXJAZ-UHFFFAOYSA-N
M.W : 171.22 Pubchem ID :675878
Synonyms :

Calculated chemistry of [ 19369-53-0 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 5
Fraction Csp3 : 0.29
Num. rotatable bonds : 2
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 44.97
TPSA : 80.56 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.88 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.01
Log Po/w (XLOGP3) : 2.06
Log Po/w (WLOGP) : 1.43
Log Po/w (MLOGP) : 0.64
Log Po/w (SILICOS-IT) : 2.09
Consensus Log Po/w : 1.65

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.4
Solubility : 0.676 mg/ml ; 0.00395 mol/l
Class : Soluble
Log S (Ali) : -3.38
Solubility : 0.0713 mg/ml ; 0.000416 mol/l
Class : Soluble
Log S (SILICOS-IT) : -1.77
Solubility : 2.93 mg/ml ; 0.0171 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.36

Safety of [ 19369-53-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 19369-53-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 19369-53-0 ]
  • Downstream synthetic route of [ 19369-53-0 ]

[ 19369-53-0 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 123-38-6 ]
  • [ 105-34-0 ]
  • [ 19369-53-0 ]
YieldReaction ConditionsOperation in experiment
73.6% With morpholine; sulfur In N,N-dimethyl-formamide at 50℃; The sulfur powder (960.0mg, 30.0mmol)In a single mouth bottle,Add DMF 5 mL,Were successively added methyl cyanoacetate (3.39g, 30.0mmol),Morpholine (1.48 g, 17.0 mmol),The reaction solution was dark brown,Propionaldehyde (1.74 g, 30.0 mmol) was added,50 ° C overnight.After completion of the reaction, the mixture was cooled to room temperature,Add appropriate amount of water,Ethyl acetate was extracted three times,The combined organic phases were washed with saturated brine,Dried over anhydrous magnesium sulfate,The crude product was distilled under reduced pressure.Separation and purification by column chromatography,To give a pale yellow solid.Yield: 73.6percent
33% for 12 h; Reflux; Inert atmosphere General procedure: A solution of aliphatic carbonyl compound 1 (2 mmol), activatednitrile (2 mol), elemental sulfur (2 mmol) and triethylamine(2 mmol) in MeOH (15 ml) was heated at reflux temperature for12 h under argon atmosphere. The MeOH was evaporated underreduced pressure and the residue was extracted with dichloromethane(3 50ml). The combined organic phases were washedwith a saturated solution of NaHCO3, dried over magnesium sulfateand the solvent was evaporated under reduced pressure. Purificationby column chromatography (silica, eluent CH2Cl2) afforded 3 asan off-white solid or a semi-solid.
Reference: [1] Patent: CN106167497, 2016, A, . Location in patent: Paragraph 0241; 0242; 0243
[2] ChemMedChem, 2018,
[3] European Journal of Medicinal Chemistry, 2017, vol. 132, p. 219 - 235
[4] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 2, p. 305 - 308
[5] Patent: WO2013/190137, 2013, A2, . Location in patent: Page/Page column 73
[6] ChemMedChem, 2014, vol. 9, # 12, p. 2744 - 2753
[7] Patent: US2015/126559, 2015, A1, . Location in patent: Paragraph 0379; 0380
[8] European Journal of Medicinal Chemistry, 2019, vol. 161, p. 239 - 251
  • 2
  • [ 19369-53-0 ]
  • [ 77287-34-4 ]
  • [ 108831-66-9 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 2, p. 305 - 308
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 19369-53-0 ]

Esters

Chemical Structure| 4815-32-1

[ 4815-32-1 ]

Ethyl 2-amino-5-methylthiophene-3-carboxylate

Similarity: 0.97

Chemical Structure| 350998-01-5

[ 350998-01-5 ]

Isopropyl 2-amino-5-methylthiophene-3-carboxylate

Similarity: 0.94

Chemical Structure| 811865-16-4

[ 811865-16-4 ]

Dimethyl 2-amino-5-methylthiophene-3,4-dicarboxylate

Similarity: 0.94

Chemical Structure| 19156-63-9

[ 19156-63-9 ]

Methyl 2-amino-5-ethylthiophene-3-carboxylate

Similarity: 0.91

Chemical Structure| 59713-53-0

[ 59713-53-0 ]

tert-Butyl 2-amino-5-methylthiophene-3-carboxylate

Similarity: 0.91

Amines

Chemical Structure| 4815-32-1

[ 4815-32-1 ]

Ethyl 2-amino-5-methylthiophene-3-carboxylate

Similarity: 0.97

Chemical Structure| 350998-01-5

[ 350998-01-5 ]

Isopropyl 2-amino-5-methylthiophene-3-carboxylate

Similarity: 0.94

Chemical Structure| 811865-16-4

[ 811865-16-4 ]

Dimethyl 2-amino-5-methylthiophene-3,4-dicarboxylate

Similarity: 0.94

Chemical Structure| 41940-47-0

[ 41940-47-0 ]

2-Amino-5-methylthiophene-3-carboxylic acid

Similarity: 0.92

Chemical Structure| 59713-53-0

[ 59713-53-0 ]

tert-Butyl 2-amino-5-methylthiophene-3-carboxylate

Similarity: 0.91